PARIS and NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE: BMY) announced today that the Canadian Federal Court of Appeals dismissed Apotex Inc.'s ("Apotex") appeal of the judgment of the Federal Court of Canada prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex in connection with its 75mg clopidogrel bisulfate tablets. Absent a Notice of Compliance, Apotex cannot market its 75mg clopidogrel bisulfate tablets in Canada.
About sanofi-aventis
Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Source: Sanofi-aventis; Bristol-Myers Squibb
